Alife Health Receives CE Mark for AI Embryo Selection Tool

Alife Health has received CE Mark certification under the European Medical Device Regulation for its AI-based embryo selection software, Embryo Predict, announced in a press release. The approval allows the company to offer the product to fertility clinics across the European Union.

Embryo Predict uses deep learning to analyze embryo images and generate an AI score ranking embryos by their likelihood of resulting in a clinical pregnancy. The platform integrates with existing laboratory infrastructure to standardize embryo grading and reduce variation between embryologists.

With regulatory clearance in place, Alife plans to begin deploying the software to selected IVF centers in Europe. The company said this expansion builds on its U.S. operations, where its clinical decision support platform is already in use through partnerships with leading fertility networks.